A practical approach to treating diffuse benign endometrial hyperplasias

Tikhomirov A.L.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation
Endometrial hyperplastic processes are the most common indications for intrauterine interventions and often for hysterectomy. It has been previously proven that a therapeutic approach to treating endometrial hyperplasia (EH) is in fact anti-recurrent after histological evaluation of a removed substrate. EH therapy using a GnRH agonist has been pathogenetically substantiated by the proven multiple mechanisms of action: from desensitization of the pituitary gland to interaction with specific receptors in endometrial cells. The offensive potential of currently available combined oral contraceptives in the prevention of recurrent EH in reproductive-aged patients who are not planning to become pregnant after a therapy cycle with a GnRH is determined primarily by the tropism of the gestagen included in the drug for the endometrium.


endometrial growths
hormonal ablation
GnRH agonists


  1. Ellsworth B.S., Burns A.T., Escudero K.W., Duval D.L., Nelson S.E., Clay C.M. The gonadotropin releasing hormone (GnRH) receptor activating sequence (GRAS) is a composite regulatory element that interacts with multiple classes of transcription factors including Smads, AP-1 and a forkhead DNA binding protein. Mol. Cell. Endocrinol. 2003; 206(1-2): 93-111.
  2. Доброхотова Ю.Э. Гиперплазия эндометрия. М.: ГЭОТАР-Медиа; 2016. 87 с. [Dobrokhotova Yu.E. Endometrial hyperplasia. M.: GEOTAR-Media; 2016. 87 p. (in Russian)].
  3. Тихомиров А.Л. Лечение больных миомой матки с использованием суперагониста гонадотропин-рилизинг-гормона. Российский вестник акушера-гинеколога. 2017; 17(5): 88-90. [Tikhomirov A.L. Treatment of patients with uterine myoma using superagonist gonadotropin-releasing hormone. Russian Bulletin of the obstetrician-gynecologist. 2017; 17(5): 88-90. (in Russian)].
  4. Bono Y., Kyo S., Kiyono T., Mizumoto Y., Nakamura M., Maida Y. et al. Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives. Fertil. Steril. 2014; 101(5): 1337-43. https://dx.doi.org/10.1016/j.fertnstert.2014.02.005.

Received 27.03.2019

Accepted 19.04.2019

About the Authors

Tikhomirov, Alexander L., MD, professor of the Department of Obstetrics and Gynecology, Medical Faculty, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of the Russian Federation. 127473, Russia, Moscow, Delegatskaya str. 20/1. Tel.: +7 495 6096700. E-mail: pacificoff@mail.ru

For citation: Tikhomirov A.L. A practical approach to treating diffuse benign endometrial hyperplasias. Akusherstvo i Ginekologiya/Obstetrics and Gynecology.2019; (4): 96-100. (in Russian)

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.